Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Risankizumab
DRUG: Lutikizumab
DRUG: Trosunilimab
DRUG: Risankizumab
DRUG: Trosunilimab
DRUG: ABBV-8736

Sponsor

AbbVie